ArticleScientific reports2025
Genetic spectrum among 2009 Iranian individuals with neuromuscular disorders using next generation sequencing and multiple ligation dependent probe amplification methods.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Variable phenotypic manifestations of two splice-site variants in DNAJB2: insights from two families and a systematic review.Journal of human genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary neuromuscular disorders (NMDs) are clinically and genetically heterogeneous, with variable severity and onset from birth to adulthood. This study retrospectively analyzes genetic findings in 2009 Iranian individuals with suspected NMDs over 11 years to highlight gene involvement and mutational patterns. Patients underwent gene panel sequencing (GPS), whole exome sequencing (WES), or MLPA for PMP22 in cases with suspected Charcot-Marie-Tooth disease type 1 A (CMT1A). The diagnostic yield of GPS/WES was 46%. Dystrophies were the most prevalent, followed by neuropathies and myopathies. The key implicated genes were CAPN3 and DMD for dystrophies; GDAP1 and MME for neuropathies; GNE and ETFDH for myopathies. The most common phenotype group was dystrophies among both individuals with childhood-onset and adulthood-onset, but the most frequent mutated gene was CAPN3 in children and DYSF in adults. Identified variants include 761 (97%) single nucleotide variants (SNVs) and 24 (3%) copy number variations (CNVs). Notably, 26% of SNVs were novel. Among individuals tested with MLPA, 28% had confirmed PMP22 gene deletions or duplications, with 73% being duplications linked to CMT1A. This large-scale analysis provides insight into the genetic landscape of NMDs in Iran. Understanding gene distribution and mutation types can improve diagnosis and inform management strategies for affected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.